Particle Therapy 2017

Both Arms :

Consolida4on

chemotherapy x 2

cycles required for

pa4ents who receive concurrent carbopla4n and paclitaxel***

*The total prescribed dose will be 70 Gy [Relative Biological Effectiveness (RBE)] without exceeding tolerance dose-volume limits of all critical normal structures .

I E Arm 1 : Photon dose—70 Gy*, at 2 Gy (RBE) once daily plus pla4num-based doublet chemotherapy Z

Arm 2 : Proton dose—70 Gy (RBE), at 2 Gy once daily plus pla4num-based doublet chemotherapy**

R

A

D

N

O

M

Stage • II PHASE III RANDOMIZED TRIAL COMPARING OVERALL SURVIVAL AFTER PHOTON VERSUS PROTON CHEMORADIOTHERAPY FOR INOPERABLE STAGE II-IIIB NSCLC Required Sample Size : 560 patients • IIIA •IIIB Histology • Squamous •Non-Squamous Concurrent Chemotherapy Doublet Type • Carbopla4n/paclitaxel • Cispla4n/etoposide

RADIATION THERAPY ONCOLOGY GROUP (RTOG 1308) NRG (RTOG) – Phase III protocol – open for accrual

I

F

S

T

T

Y

R

A